- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03237871
The EMERGE Project: Feasibility of Assessing Economic and Sexual Risk Behaviors Using Text Messages in Young Adults
April 10, 2019 updated by: Johns Hopkins Bloomberg School of Public Health
The Engaging Microenterprise for Resource Generation and Health Empowerment (EMERGE) Project: Feasibility of Assessing Economic and Sexual Risk Behaviors Using Text Messages in Homeless Young Adults
As part of the development of the Engaging Microenterprise for Resource Generation and Health Empowerment (EMERGE) Project, the study team will conduct a single-group study to examine the feasibility of assessing economic and sexual risk behaviors using text messages.
The team will enroll approximately 20 young adults, aged 18 to 24, who are African-American, homeless, out-of-school, and un/under-employed.
Participants will complete a text-messaged survey each week for 5 weeks.
The study team will collect information about the number of participants who respond to the weekly survey, the number of questions to which they respond in each survey, and the number of hours from sending a survey to participants to receiving their response.
As an exploratory aim, participants will also receive 3 informational text messages each week for 5 weeks on HIV prevention and economic empowerment.
The study team will obtain qualitative feedback from participants regarding text messages they most and least liked.
The survey is not designed to evaluate the effectiveness of the text message intervention.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
As part of the development of the Engaging Microenterprise for Resource Generation and Health Empowerment (EMERGE) Project, the study team will conduct a single-group study to examine the feasibility of assessing economic and sexual risk behaviors using text messages.
The study team will enroll approximately 20 young adults, aged 18 to 24, who are African-American, homeless, out-of-school, and un/under-employed.
Participants will complete a text-messaged survey each week for 5 weeks.
The study team will collect information about the number of participants who respond to the weekly survey, the number of questions to which they respond in each survey, and the number of hours from sending a survey to participants to receiving their response.
As an exploratory aim, participants will also receive 3 informational text messages each week for 5 weeks on HIV prevention and economic empowerment.
The study team will obtain qualitative feedback from participants regarding text messages they most and least liked.
The survey is not designed to evaluate the effectiveness of the text message intervention.
The single-group study is anticipated to start in August 2017.
Study Type
Interventional
Enrollment (Actual)
17
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins Bloomberg School of Public Health
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 24 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Individuals will be included in the study if, at the time of enrollment, they are:
- African American
- Aged 18-24
- Living in Baltimore City
- Experiencing homelessness in the past 12 months
- Employed fewer than 10 hours per week
- Not enrolled in school
- Ownership of a mobile phone with text-messaging capacity
- Reporting at least one episode of unprotected sex in prior 6 months or one other personal or sexual partner HIV risk factor within prior 6 months (STI diagnosis, sex while high or drunk, sex exchange, illicit drug use, alcohol dependence).
Exclusion Criteria:
- Aged 17 or younger.
- Older than 24 years
- Unwilling to provide consent for study participation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Survey and informational text messages
Text-message survey and informational text messages
|
Participants will complete a text-messaged survey each week for 5 weeks assessing economic and sexual risk behaviors.
Participants will also receive 3 informational text messages each week for 5 weeks on HIV prevention and economic empowerment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Who Respond to the Survey in Week 1
Time Frame: Week 1
|
Number of enrolled participants who respond to the survey in Week 1. Measure type 'number' was used for small sample size and as described in the original registration protocol.
|
Week 1
|
Mean Number of Questions to Which Participant Respond in Each Survey in Week 1
Time Frame: Week 1
|
Mean number of questions to which enrolled participant respond in each survey in Week 1.
|
Week 1
|
Mean Number of Hours From Sending a Survey to Participants to Receiving Their Response in Week 1
Time Frame: Week 1
|
Mean number of hours from sending a survey to enrolled participants to receiving their response in Week 1.
|
Week 1
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Larissa Jennings, PhD MHS, Johns Hopkins Bloomberg School of Public Health
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 7, 2017
Primary Completion (Actual)
September 19, 2017
Study Completion (Actual)
September 19, 2017
Study Registration Dates
First Submitted
July 25, 2017
First Submitted That Met QC Criteria
July 31, 2017
First Posted (Actual)
August 3, 2017
Study Record Updates
Last Update Posted (Actual)
April 12, 2019
Last Update Submitted That Met QC Criteria
April 10, 2019
Last Verified
April 1, 2019
More Information
Terms related to this study
Other Study ID Numbers
- IRB0007563
- K01MH107310 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
All de-identified IPD that underlie results in a publication will be shared.
IPD Sharing Time Frame
De-identified individual patient data (IPD) that under results in a publication will become available 12 months after publication and will be available for 24 months.
IPD Sharing Access Criteria
Sponsor approval for data sharing will be sought.
Only bona fide research groups are eligible to access data as evidenced via curriculum vitae (CV) and the involvement of a qualified statistician or qualitative research scientist.
Data access requests should be made via email application to the principal investigator detailing the specific requirements and the proposed research and publication plan.
Data access requests will be reviewed against specific criteria by the data custodians.
Decisions about requests will be made promptly and no more than 3 months after receipt of request.
IPD Sharing Supporting Information Type
- Study Protocol
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Feasibility
-
Kliniken Ludwigsburg-Bietigheim gGmbHUnknownFeasibility, ComplicationsGermany
-
Baylor College of MedicineUniversity of PittsburghRecruitingFeasibility | Diet, HealthyUnited States
-
Johns Hopkins Bloomberg School of Public HealthNational Institute of Mental Health (NIMH)CompletedFeasibilityUnited States
-
University of Southern DenmarkEuropean Research CouncilCompleted
-
Hospital for Special Surgery, New YorkRecruitingFeasibility | Total Knee Replacement | MediationUnited States
-
University of California, San FranciscoEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedFeasibility | Unintended Pregnancy | Family Planning | AcceptabilityIndia
-
Washington University School of MedicineMallinckrodtCompletedHealthy Volunteers | Mobile Applications | Feasibility StudyUnited States
-
Duke UniversityUniversity of Colorado, Denver; Northwestern University; University of California... and other collaboratorsCompletedFeasibility of Best Supportive Care Delivery
-
University of California, San DiegoCompletedMedical Device | Feasibility StudyUnited States
Clinical Trials on Text-message survey and informational text messages
-
Imperial College LondonBarts & The London NHS Trust; Mid and South Essex NHS Foundation Trust; Royal... and other collaboratorsCompleted
-
Thomas Jefferson UniversityWithdrawnAcute Myeloid LeukemiaUnited States
-
Massachusetts General HospitalBrigham and Women's HospitalCompletedSkin CancerUnited States
-
University of California, San FranciscoMyovant Sciences GmbHRecruitingLeveraging Technology to Achieve Equity for Men With Prostate Cancer on Androgen Deprivation TherapyProstate CancerUnited States
-
Emory UniversityNational Cancer Institute (NCI)RecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphoid System NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute...Active, not recruitingFamily Member | Health Status UnknownUnited States
-
Wake Forest University Health SciencesCompleted
-
Thomas Jefferson UniversityCompletedChronic Phase Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); The Safeway FoundationCompletedTobacco Use DisorderUnited States
-
Fred Hutchinson Cancer CenterNational Institute on Drug Abuse (NIDA)Active, not recruitingNicotine Dependence | Nicotine Use Disorder | Nicotine Vaping | Vaping | Nicotine AddictionUnited States